• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    7/2/26 5:00:33 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    false 0001739174 0001739174 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 1, 2026

     

    BIOMX INC.

    (Exact name of registrant as specified in its charter)

     

     Delaware   001-38762   82-3364020
    (State or other jurisdiction of
    incorporation or organization)
      (Commission File Number)   (IRS Employer
    Identification Number)

     

    850 New Burton Road, Suite 201, Dover, DE 19904

    (Address of principal executive offices)

     

    972 52 437 4900

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

      Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   PHGE   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a) Dismissal of Independent Registered Public Accounting Firm.

     

    On July 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of BiomX Inc. (the “Company”) determined, and the Board subsequently ratified and confirmed, to dismiss Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited (“PwC”), as the Company’s independent registered public accounting firm. The dismissal of PwC became effective automatically upon, and simultaneously with, the effectiveness of the engagement of Barzily & Co., Certified Public Accountants (Isr.) (“Barzily”), described under Item 4.01(b) below, which occurred on July 1, 2026 (such date, the “Dismissal Date”).

     

    The reports of PwC on the Company’s consolidated financial statements for each of the fiscal years ended December 31, 2024 and December 31, 2025 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to audit scope or accounting principles, except that each such report included an explanatory paragraph expressing substantial doubt as to the Company’s ability to continue as a going concern.

     

    The decision to dismiss PwC was recommended and approved by the Audit Committee and was ratified and approved by the Board.

     

    During the Company’s two most recent fiscal years ended December 31, 2024 and December 31, 2025, and the subsequent interim period through the Dismissal Date, there were no disagreements between the Company and PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to PwC’s satisfaction, would have caused PwC to make reference to the subject matter of the disagreement in connection with its reports.

     

    During the Company’s two most recent fiscal years ended December 31, 2024 and December 31, 2025, and the subsequent interim period through the Dismissal Date, there were no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

    The Company has provided PwC with a copy of the disclosures set forth in this Item 4.01(a) and has requested that PwC furnish the Company with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether PwC agrees with the statements made herein and, if not, stating the respects in which it does not agree. The Company will file such letter as Exhibit 16.1 to an amendment to this Current Report on Form 8-K within two business days of the Company’s receipt thereof.

     

    (b) Engagement of New Independent Registered Public Accounting Firm.

     

    On July 1, 2026, the Audit Committee approved, and the Board ratified and confirmed, the engagement of Barzily as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026, effective as of July 1, 2026. Barzily’s engagement is memorialized in an engagement letter dated June 16, 2026, executed by the Chairperson of the Audit Committee on behalf of the Company on July 1, 2026.

     

    During the Company’s two most recent fiscal years ended December 31, 2024 and December 31, 2025, and the subsequent interim period prior to Barzily’s engagement, neither the Company nor anyone on its behalf consulted with Barzily regarding either (i) the application of accounting principles to a specified completed or proposed transaction, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company by Barzily that was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K, or a “reportable event,” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    16.1   Letter from Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, to the Securities and Exchange Commission.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized..

     

      BIOMX INC
         
      Date: July 2, 2026
         
      By: /s/ Michael Oster
      Name: Michael Oster
      Title: Chief Executive Officer
         

     

    2

     

    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities

    NETANYA, Israel, July 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced that its wholly owned subsidiary Zorronet has completed the transition of its core operations to a new data center. The new data center is designed to improve response times and cost efficiency, and to increase capacity for handling complex security events in real time. The new data center forms a key part of Zorronet’s infrastructure modernization and supports its business expansion. "Completing the transition to a new advanced data center is an important milestone," said Idan Wasserman, CE

    7/10/26 7:25:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities

    NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on acquiring and further developing technologies that identify, analyze, protect against and support faster responses to physical threats, today announced that its wholly owned subsidiary BiomX Israel Defense and Security Ltd. has signed a non-binding letter of intent (the "LOI") to acquire a 60% controlling interest in Tsoock Defense Technologies Ltd. ("Tsoock"), an Israeli security infrastructure and systems integration company with approximately 20 years of operating experience. The LOI is non-binding with respect to the proposed transaction terms, and there can be no

    7/8/26 7:05:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement

    NETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), announced today following its April 16, 2026 announcement that its wholly-owned subsidiary Zorronet has commenced supply and installation of its AI and ML-powered detection and command-and-control systems on sections of the Israel Railways network, in accordance with the framework supply agreement, focused on protecting wildlife and safeguarding national infrastructure. Zorronet provides and installs AI, ML and business intelligence-enabled alert stations capable of detecting and deterring animals and humans, including ongoing maintenance and 24/7 service center operations. The initial ph

    7/6/26 8:32:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Yeganeh Reuven sold $3,350,000 worth of shares (670,000 units at $5.00) and converted options into 670,000 shares (SEC Form 4)

    4 - BiomX Inc. (0001739174) (Issuer)

    3/13/26 4:30:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bidas Liat Cohavi

    3 - BiomX Inc. (0001739174) (Issuer)

    3/3/26 9:27:51 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    SEC Filings

    View All

    SEC Form PRE 14A filed by BiomX Inc.

    PRE 14A - BiomX Inc. (0001739174) (Filer)

    7/17/26 5:00:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by BiomX Inc.

    EFFECT - BiomX Inc. (0001739174) (Filer)

    7/15/26 12:15:16 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by BiomX Inc.

    424B3 - BiomX Inc. (0001739174) (Filer)

    7/14/26 5:10:29 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Provides Update on Defense Technology Portfolio and Growth Strategy

    NETANYA, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), a company that develops and acquires technologies for defense, security, and first-response markets, today announced that it has posted an updated informational presentation to the Company's website as part of its completed strategic transition towards the defense sector. The presentation provides an overview of BiomX's portfolio, operating framework, leadership and advisory team, and growth strategy. BiomX's current strategy is built around the growing need for technologies that can identify, analyze, and support faster responses to physical threats across high-consequence settings. The Company's portfolio current

    6/18/26 9:15:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

    NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

    4/10/26 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care